Clinical trial
Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients…
NCT00311363 · XenoPort, Inc., Industry · Completed
Key facts
| NCT number | NCT00311363 |
|---|---|
| Title | Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome. |
| Official title | A Long-Term Study of XP13512 Versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients With Restless Legs Syndrome. |
| Lead sponsor | XenoPort, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Restless Legs Syndrome |
| Intervention type | Drug |
| Interventions | GEn (XP13512), Placebo |
| Enrollment | 327 |
| Start date | Apr 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Apr 5, 2006 |
| Last update posted | Jul 22, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: